GHRP-2

Mechanism

An injectable peptide that tells your pituitary gland to release growth hormone. It's considered the most selective of the classic GH-releasing peptides — meaning it gives you a strong GH pulse with less impact on hunger, cortisol, and prolactin compared to GHRP-6.

Effects

ENDOCRINE / GH AXIS [Tier 1 – Human Clinical]: GHRP-2 (Growth Hormone Releasing Peptide-2, also known as Pralmorelin) is a selective hexapeptide ghrelin receptor agonist that produces potent GH release with a cleaner hormonal profile than GHRP-6. GH elevation is comparable to GHRP-6 (3-5x baseline) but with significantly less appetite stimulation, lower cortisol impact, and moderate prolactin elevation. Approved in Japan as a GH stimulation test (Pralmorelin/GHRP Kaken 100). One of the best-characterized GHRPs in clinical literature. APPETITE [Tier 1 – Human Clinical]: Mild to moderate appetite stimulation — substantially less than GHRP-6 but more than Ipamorelin. This makes GHRP-2 the "middle ground" GHRP — potent GH release without overwhelming hunger. Some patients experience no appetite change at all. Ghrelin-like signaling is present but attenuated compared to GHRP-6. METABOLIC [Tier 2 – Limited Human]: Mild cortisol elevation (less than GHRP-6 or hexarelin). Moderate prolactin elevation (more than Ipamorelin, less than hexarelin). These off-target effects are generally clinically insignificant at standard doses but should be monitored. CARDIOVASCULAR [Tier 2 – Limited Human]: Some cardioprotective properties via ghrelin receptor activation, but substantially less than hexarelin (which has unique CD36 binding). May provide modest cardiac benefit as a class effect of ghrelin receptor agonists. MUSCULOSKELETAL [Tier 2 – Limited Human]: Through GH/IGF-1 elevation, supports anabolic processes, recovery, and connective tissue repair. Similar indirect anabolic benefits to other GHRPs. Combined with GHRH analog, produces robust and sustained GH optimization.

Practitioner Guide

CLINICAL POSITIONING: GHRP-2 is the "Goldilocks" GHRP — more potent than Ipamorelin, cleaner than GHRP-6, less problematic than hexarelin. For practitioners building GH optimization protocols, GHRP-2 occupies the sweet spot between efficacy and side effect profile. It is the most commonly prescribed GHRP in Japanese clinical medicine (as Pralmorelin). WHERE GHRP-2 FITS IN THE GHRP HIERARCHY: • Ipamorelin: Cleanest. Minimal cortisol/prolactin. Mildest GH release. Best for sensitive patients, women, long-term use. • GHRP-2: Balanced. Moderate cortisol/prolactin. Strong GH release. Best all-around GHRP for most patients. • GHRP-6: Potent but hungry. Significant appetite stimulation. Best for underweight, muscle gain phases. • Hexarelin: Most potent. Most side effects. Fastest desensitization. Best for short-term cardiac protocols. DOSING PROTOCOLS: • Standard: 100-300 mcg subcutaneous, 2-3x daily (AM fasted, post-workout, pre-bed). • Conservative start: 100 mcg 2x daily (AM + pre-bed) for first 2 weeks, then escalate. • Optimal: 200 mcg 3x daily for maximum GH optimization (saturation dose is approximately 1-2 mcg/kg per injection). • Timing: Empty stomach, 2+ hours post-meal. Wait 20-30 min before eating. DESENSITIZATION PROFILE: • GHRP-2 desensitizes slower than hexarelin but faster than Ipamorelin. • Expect gradual GH response attenuation over 8-16 weeks of continuous daily use. • Cycling: 8-12 weeks on, 4 weeks off. OR 5 days on / 2 days off weekly to extend run time. • Combining with GHRH analog (Mod GRF 1-29 or CJC-1295) partially mitigates desensitization by driving GH release through a second pathway. THE GHRP-2 + MOD GRF 1-29 PROTOCOL (GOLD STANDARD): • This is considered the optimal pulsatile GH optimization stack by most experienced practitioners. • Dose: GHRP-2 200 mcg + Mod GRF 1-29 100 mcg, injected together subcutaneously, 2-3x daily. • Can be drawn into the same syringe. Both are stable in solution. • Synergistic GH release: 3-5x greater than either peptide alone. • Timing: Fasted AM, post-workout (if training), pre-bed. Pre-bed dose is most important (amplifies nocturnal GH surge). BLOOD WORK MONITORING: • Baseline: IGF-1, fasting glucose, insulin, HbA1c, prolactin, cortisol AM. • 6-week: IGF-1 (target 200-350 ng/dL depending on age and goals), prolactin (should remain <20 ng/mL in men), fasting glucose/insulin. • 12-week: Full panel. Assess for desensitization (IGF-1 trending down). If desensitization evident, begin off-cycle. SIDE EFFECTS: • Mild appetite stimulation: Less intrusive than GHRP-6. Usually manageable. • Prolactin elevation: Monitor. If prolactin >20 ng/mL (men) or symptomatic, consider P5P (100-200 mg/day) or switch to Ipamorelin. • Water retention: First 2 weeks, self-resolving. • Cortisol: Mild, transient. Usually clinically insignificant. • If ANY carpal tunnel symptoms or significant joint swelling, GH effect is too strong — reduce dose or frequency.

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  GHRP-2 elevates GH and IGF-1 via ghrelin receptor agonism. IGF-1 is mitogenic and promotes cell proliferation, inhibits apoptosis, and may accelerate tumor growth.
  Action: Do not use in patients with any active cancer. Cancer survivors should obtain oncologist clearance.
• hard stop — Pregnancy
  No human safety data during pregnancy. GH/IGF-1 elevation poses risk to fetal development.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GH-axis peptides are not designed for unsupervised pediatric use.
  Action: Do not provide to individuals under 18.
• requires physician — Diabetes
  GH elevation antagonizes insulin action. GHRP-2 also raises cortisol and ACTH, which further impair glucose tolerance. May worsen glycemic control in diabetic patients.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory.
• requires physician — Cushing syndrome or hypercortisolism
  GHRP-2 stimulates ACTH and cortisol release in addition to GH. Patients with Cushing syndrome or adrenal disorders may experience dangerous cortisol elevation.
  Action: Requires endocrinologist evaluation. Monitor cortisol levels.

Evidence

• Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature

  Pihoker C, Middleton R, Reynolds GA, Bowers CY, Rogol AD (1995) — Journal of Clinical Endocrinology and Metabolism — PMID: 7673411

  GHRP-2 administered IV and intranasally effectively stimulated GH release in children with short stature. Demonstrated utility as a diagnostic tool for GH deficiency with a robust and reproducible GH response. Intranasal route showed clinical feasibility for pediatric testing.

  moderate

• Growth hormone-releasing peptide (GHRP)

  Bowers CY, Momany FA, Reynolds GA, Hong A (1984) — Endocrinology — PMID: 6430132

  Bowers and colleagues characterized the first synthetic GH-releasing peptides, demonstrating dose-dependent GH release in vitro and in vivo. This work established the GHRP family as a novel class of GH secretagogues acting through a distinct mechanism from GHRH, later identified as the ghrelin receptor pathway.

  moderate

Stacks featuring this peptide

Research Summary

TIER 1 (Human Clinical Trials): • Bowers et al. (1990s series): Characterized GHRP-2 GH release kinetics. Dose-dependent response, synergistic with GHRH. • Arvat et al. (1997): Head-to-head comparison with other GHRPs — GHRP-2 showed potent GH release with intermediate hormonal side effects (between Ipamorelin and hexarelin). • Japanese clinical data (Pralmorelin/GHRP Kaken): Approved as GH stimulation test. Extensive safety database from diagnostic use. • Anderson et al. (2001): Chronic dosing studies showing sustained GH and IGF-1 elevation with gradual attenuation over weeks. TIER 2 (Limited Human / Strong Preclinical): • Selectivity profiling: GHRP-2 shows preferential GHS-R1a binding with reduced affinity for cortisol/prolactin-mediating pathways compared to GHRP-6. • Desensitization kinetics: Intermediate between Ipamorelin (slowest) and hexarelin (fastest). • Synergy studies with GHRH analogs confirming supra-additive GH release when combined. TIER 3 (Preclinical / Mechanistic): • Animal models: Improved body composition, enhanced wound healing, neuroprotective effects. • Cardiac protective effects via ghrelin receptor activation (less potent than hexarelin). • Sleep architecture studies showing enhancement of slow-wave sleep with pre-bed dosing. EVIDENCE GAPS: No Phase III therapeutic trials (only diagnostic approval in Japan). Optimal long-term dosing not established by controlled trials. Head-to-head comparison with Ipamorelin for chronic GH optimization not performed. Desensitization cycling protocols based on practitioner experience, not clinical evidence.